Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study.
Renée Maria Saliby(Yale University), Toni K. Choueiri(Harvard University), Audreylie Lemelin(University of Calgary), J. Connor Wells(Queen's University), Karl Semaan(Broad Institute), José Manuel Ruiz-Morales(Hospital Médica Sur), Kosuke Takemura(Japanese Foundation For Cancer Research), Wanling Xie(Dana-Farber Cancer Institute), David A. Braun(Yale Cancer Center), Lori Wood(Dalhousie University), Cristina Suárez(Complejo Hospitalario de Salamanca), Hedyeh Ebrahimi(City of Hope), Guillermo de Velasco(Dana-Farber Cancer Institute), Marc Eid(Harvard University), Thomas Powles(National Health Service), Evan Ferrier, Neeraj Agarwal(University of Utah), Chris Labaki(Beth Israel Deaconess Medical Center), Daniel Yick Chin Heng(University of Calgary), Eddy Saad(Dana-Farber Cancer Institute)
Cited by 1
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
|Nature Medicine|2020|1k
The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
|Cancer Cell|2014|867